Trial Profile
Antiemetic effectiveness and safety of aprepitant in patients with lung cancer receiving combination therapy with carboplatin.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2017
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Antiemetics
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 15 Feb 2013 New trial record